Home / Crime and Justice / Pharma Giant's Vials: Counterfeit Concerns Rise
Pharma Giant's Vials: Counterfeit Concerns Rise
13 Apr
Summary
- Pharma company lacks visibility into used vial disposal.
- Disposal of used packaging follows local regulations.
- Company aids police in counterfeit Keytruda investigations.
Responsibility for the disposal of used medicinal packaging rests with individual healthcare facilities, according to a statement from MSD, an international subsidiary of Merck & Co. This statement addresses concerns arising from an investigation into a growing counterfeit market for their cancer drug, Keytruda.
The company indicated that once its products are delivered through the legitimate supply chain, it loses visibility into the subsequent handling of vials or packaging. Therefore, the disposal of such materials is governed by local regulations and the specific procedures implemented by healthcare institutions.
When questioned about actions taken following the seizure of Keytruda batches by Delhi Police from hospital personnel, MSD confirmed its cooperation. The company analyzed the seized samples at its Forensic Services Laboratory and shared the findings with the police, routinely assisting law enforcement with technical and product-related information when requested.
MSD also stated that it does not currently have a system in place to track individual drug units from a specific batch to ensure they are used only once and then disposed of in a prescribed manner after clinical use. The company reiterated that investigative and enforcement responsibilities lie with competent authorities, with its role being supportive and cooperative.
